Cibus Yönetim

Yönetim kriter kontrolleri 2/4

Cibus CEO'su Rory Riggs, Jan2001 tarihinde atandı, in görev süresi 23.83 yıldır. in toplam yıllık tazminatı $ 292.31K olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 13.12% ine doğrudan sahiptir ve bu hisseler $ 15.40M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 1.4 yıldır.

Anahtar bilgiler

Rory Riggs

İcra Kurulu Başkanı

US$292.3k

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	23.8yrs
CEO sahipliği	13.1%
Yönetim ortalama görev süresi	5.1yrs
Yönetim Kurulu ortalama görev süresi	1.4yrs

Son yönetim güncellemeleri

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

CEO Tazminat Analizi

Rory Riggs'un ücretlendirmesi Cibus'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$445m
Jun 30 2024	n/a	n/a	-US$292m
Mar 31 2024	n/a	n/a	-US$286m
Dec 31 2023	US$292k	US$292k	-US$268m

Tazminat ve Piyasa: Rory 'nin toplam tazminatı ($USD 292.31K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 652.28K ).

Tazminat ve Kazançlar: Rory şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Rory Riggs (71 yo)

23.8yrs

Görev süresi

US$292,314

Tazminat

Mr. Rory Balfour Riggs, MBA, serves as Chief Executive Officer of Cibus, Ltd. since October 2021. He is Co-Founder at Cibus, Inc. and is its Chief Executive Officer and Chairman since June 1, 2023.Mr. Rig...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rory Riggs	Co-Founder	23.8yrs	US$292.31k	13.12% $ 15.4m
Peter Beetham	Co-Founder	1.4yrs	US$292.31k	0.29% $ 336.3k
Greg Gocal	Co-Founder	8.8yrs	US$266.01k	0.24% $ 279.4k
Jason Stokes	Chief Legal Officer	less than a year	Veri yok	Veri yok
Rosa Kim	Senior Vice President of Legal	no data	Veri yok	Veri yok
James Radtke	Senior Vice President of Product Development	no data	Veri yok	Veri yok
Tony Moran	Senior Vice President of International Development	no data	Veri yok	Veri yok
Norm Sissons	Senior Vice President of Seed & Traits	no data	Veri yok	Veri yok
Noel Sauer	Senior Vice President of Research	no data	Veri yok	Veri yok
Sean O'Connor	Senior VP and President & CEO of Nucelis	no data	Veri yok	Veri yok

5.1yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: CBUS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rory Riggs	Co-Founder	1.4yrs	US$292.31k	13.12% $ 15.4m
Peter Beetham	Co-Founder	1.4yrs	US$292.31k	0.29% $ 336.3k
Gerhard Prante	Independent Vice Chairman	1.4yrs	Veri yok	0.27% $ 318.5k
Mark Finn	Lead Independent Director	1.4yrs	Veri yok	0.25% $ 289.4k
Keith Walker	Independent Director	1.4yrs	Veri yok	0.32% $ 373.5k
Joseph Ecker	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jean-Pierre Lehmann	Independent Director	1.4yrs	Veri yok	6.65% $ 7.8m
Jan Leach	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephen Howell	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Richard Meagher	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

1.4yrs

Ortalama Görev Süresi

78yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CBUS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Cibus Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc., Annual General Meeting, May 30, 2024

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Cibus, Inc. Appoints Jim Collins to Board of Directors

Recent updates

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022